Freenome, Inc. (FRNM) Stock Price & Analysis
Freenome, Inc. (FRNM) closed at USD 12.29 on Thursday, October 15, 2026, up 0.78% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 12.19; the Oct 15, 2026 session ranged USD 11.7–12.64 on volume of 777,232 shares. Market capitalization is $1.32B, with a 52-week range of USD 9.95–17.5 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FRNM.md
Key facts (FRNM)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 18 (range 17–21).
- Total return with dividends: 1Y +15.5% vs S&P 500 +18.1%; 5Y +22.0% vs S&P 500 +85.1%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FRNM)
| USD | FY2025 | TTM |
|---|---|---|
| Operating income | -$3.0M | -$4.3M |
| Net income | $837K | -$763K |
| Cash + short-term investments | $865K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (FRNM)
Earnings yield -0.06%
Analysts (FRNM)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 18 (low 17, high 21).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | Guggenheim | Initiated | Buy | $21 |
| 2026-08-18 | TD Cowen | Initiated | Buy | $17 |
| 2026-08-17 | Jefferies | Initiated | Buy | $17 |
| 2026-08-17 | BTIG | Initiated | Buy | $17 |
Total return (dividends reinvested) (FRNM)
| 1Y (from 2025-10-16) | 5Y (from 2024-06-10) | |
|---|---|---|
| Total return | +15.5% | +22.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +15.5% | +8.8% |
| Volatility (annualized) | 45.3% | 30.6% |
| Max drawdown | -29.6% (Jan 2026→Jul 2026) | -28.2% (Sep 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 12.29 |
|---|---|
| Change | ▲ 0.78% (up) |
| Previous Close | USD 12.19 |
| Open | USD 12.08 |
| Day Range | USD 11.7 – 12.64 |
| 52-Week Range | USD 9.95 – 17.5 |
| Volume | 777,232 shares |
| Market Cap | $1.32B |
| Exchange | NCM |
Technical Analysis (FRNM)
Nexqual's technical model rates FRNM "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.33 (neutral) |
| vs SMA50 | Below (USD 14.56) |
| MACD | -0.5 (negative) |
Analyst Ratings (FRNM)
Wall Street analysts rate FRNM "Buy" based on 5 analysts, with a mean price target of USD 18 (range USD 17–21), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 18 |
| High Target | USD 21 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (FRNM)
| EPS Estimate | USD -0.2 |
|---|---|
| Revenue Estimate | $84.85M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (FRNM)
| Total Revenue | $35.41M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +106.50% |
| Gross Margin | +0.00% |
| Operating Margin | -2867.50% |
| Profit Margin | +0.00% |
| Current Ratio | 1.05 |
| Total Cash | $102.02M |
| Total Debt | $311.45M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (FRNM)
Nexqual rates Freenome, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +107% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $102M cash vs $311M debt |
| Cash Flow | Weak — Operating cash flow -$865K (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (FRNM)
| Insider Ownership | +25.95% |
|---|---|
| Institutional Ownership | +39.66% |
| Shares Outstanding | 107.45M |
| Float | 49.78M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (FRNM)
Freenome, Inc. is led by Aaron Elliott (age 45), CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Director | Aaron Elliott (age 45) |
|---|---|
| Co-Founder & Chief Product Officer | Riley Ennis (age 31) |
| Chief Financial Officer | Linh H. Le (age 57) |
| Chief Scientific Officer | Cheng-Ho Lin M.D., MHS (age 46) |
| Senior Vice President of Regulatory & Quality | Sally Howard |
Major Backers & Investors (FRNM)
Notable institutional backers of Freenome, Inc. include ARK Invest, Fidelity, Wealth Enhancement Advisory Services, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 2.57% |
| Fidelity | 0.62% |
| Wealth Enhancement Advisory Services, LLC | 0.27% |
| T. Rowe Price | 0.22% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OPK | Opko Health, Inc. | USD 1.61 | ▲ 21.97% |
| CSTL | Castle Biosciences, Inc. | USD 33.8 | ▲ 2.8% |
| PSNL | Personalis, Inc. | USD 15.93 | ▲ 0.5% |
| WGS | GeneDx Holdings Corp. | USD 70.22 | ▲ 8.1% |
| NEO | NeoGenomics, Inc. | USD 17.25 | ▲ 3.54% |
| FLGT | Fulgent Genetics, Inc. | USD 21.34 | ▲ 1.33% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt